Header cover image

Italian (Borsa Italiana) Biotech Industry Analysis

UpdatedApr 19, 2024
DataAggregated Company Financials
Companies3
  • 7D0.5%
  • 3M3.3%
  • 1Y17.3%
  • YTDn/a

In the last week, the Biotech industry is up 2.2%, with all of the companies up. This means that the industry has gained 13% over the past year. Looking forward, earnings are forecast to decline by 79% per year.

Industry Valuation and Performance

Has the Italian Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 20 Apr 2024€778.4m€29.4m-€6,852,735.0012.9x-113.6x26.5x
Mon, 18 Mar 2024€750.1m€33.9m-€375,735.001123.3x-1996.3x22.1x
Wed, 14 Feb 2024€724.2m€33.9m-€375,735.001080.9x-1927.4x21.4x
Fri, 12 Jan 2024€765.4m€33.9m-€375,735.001138x-2037x22.6x
Sun, 10 Dec 2023€749.0m€33.9m-€375,735.001150.7x-1993.5x22.1x
Tue, 07 Nov 2023€750.1m€33.9m-€375,735.001154x-1996.4x22.1x
Thu, 05 Oct 2023€497.9m€33.8m€1.3m11.5x383x14.7x
Sat, 02 Sep 2023€509.4m€31.9m-€5,269,721.009.9x-96.7x16x
Mon, 31 Jul 2023€488.0m€31.9m-€5,269,721.0010.7x-92.6x15.3x
Wed, 28 Jun 2023€483.9m€32.4m-€5,269,721.0011.5x-91.8x14.9x
Fri, 26 May 2023€465.3m€32.4m-€5,269,721.0010.3x-88.3x14.4x
Sun, 23 Apr 2023€464.1m€32.4m-€5,269,721.0011.8x-88.1x14.3x
Tue, 21 Mar 2023€480.4m€28.7m-€4,740,218.0010.9x-101.3x16.7x
Thu, 16 Feb 2023€493.2m€28.7m-€4,740,218.0012.2x-104.1x17.2x
Sat, 14 Jan 2023€431.5m€28.7m-€4,740,218.0011.1x-91x15x
Mon, 12 Dec 2022€434.3m€28.7m-€4,740,218.0010.2x-91.6x15.1x
Wed, 09 Nov 2022€437.8m€28.7m-€4,740,218.009.1x-92.4x15.3x
Fri, 07 Oct 2022€411.0m€23.5m-€4,296,995.009x-95.6x17.5x
Sun, 04 Sep 2022€445.3m€10.0m-€15,218,052.0012.5x-29.3x44.6x
Tue, 02 Aug 2022€440.6m€10.0m-€15,218,052.0012.7x-29x44.1x
Thu, 30 Jun 2022€453.6m€10.0m-€15,218,052.0012.6x-29.8x45.4x
Sat, 28 May 2022€442.9m€10.0m-€15,218,052.0012.8x-29.1x44.3x
Mon, 25 Apr 2022€421.5m€10.0m-€15,218,052.0013.1x-27.7x42.2x
Wed, 23 Mar 2022€423.7m€10.9m-€12,178,186.0054.9x-34.8x39x
Fri, 18 Feb 2022€476.8m€10.9m-€12,178,186.0056.3x-39.2x43.9x
Sun, 16 Jan 2022€454.5m€10.2m-€12,359,089.0016.9x-36.8x44.7x
Tue, 14 Dec 2021€461.8m€10.2m-€12,359,089.0016.7x-37.4x45.5x
Thu, 11 Nov 2021€444.9m€10.2m-€12,359,089.0019.6x-36x43.8x
Sat, 09 Oct 2021€477.5m€10.2m-€12,359,089.0020.5x-38.6x47x
Mon, 06 Sep 2021€519.6m€10.5m-€12,176,390.0022.8x-42.7x49.4x
Wed, 04 Aug 2021€437.1m€10.5m-€12,176,390.0021.8x-35.9x41.6x
Sat, 08 May 2021€466.9m€10.5m-€12,176,390.0022.3x-38.3x44.4x
Price to Earnings Ratio

-38.3x


Total Market Cap: €466.9mTotal Earnings: -€12,176,390.00Total Revenue: €10.5mTotal Market Cap vs Earnings and Revenue0%0%0%
Italian Biotech Industry Price to Earnings3Y Average -359.6x202220232024
Current Industry PE
    There are only 3 companies in the Italian Biotechnology industry, so there is insufficient data to make an industry-wide assessment of both the PE and PS ratio.
Past Earnings Growth
  • The earnings for companies in the Biotechnology industry have improved over the last three years.
  • Revenues for these companies have grown 41% per year.
  • This means that more sales are being generated by these companies overall, and subsequently losses are decreasing too.

Industry Comparison

How does Italian Biotech compare with similar industries?

IT Market0.14%
Healthcare1.68%
Biotech0.45%
Biotech0.45%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
PHIL Philogen€18.250.6%
+€4.0m
23.3%PS29.7x
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.